H-SNWKWWPGIFD-OH
Ref. 3D-PP48217
| 1mg | 248.00 € | ||
| 10mg | 292.00 € | ||
| 100mg | 481.00 € |
Product Information
Peptide H-SNWKWWPGIFD-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SNWKWWPGIFD-OH include the following: Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy Y Takahashi, Y Okamoto, HA Popiel, N Fujikake - Journal of Biological , 2007 - ASBMBhttps://www.jbc.org/article/S0021-9258(20)54387-1/abstract A toxic monomeric conformer of the polyglutamine protein Y Nagai , T Inui , HA Popiel, N Fujikake - Nature structural & , 2007 - nature.comhttps://www.nature.com/articles/nsmb1215 Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila Y Nagai , N Fujikake, K Ohno - Human molecular , 2003 - academic.oup.comhttps://academic.oup.com/hmg/article-abstract/12/11/1253/555306 Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis Y Nagai , HA Popiel - Current pharmaceutical design, 2008 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cpd/2008/00000014/00000030/art00006 Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases Y Nagai - Rinsho Shinkeigaku= Clinical Neurology, 2009 - europepmc.orghttps://europepmc.org/article/med/20030247 By KIMBERLY L. SCIARRETTA, DAVID J. GORDON, and SC MEREDITH - Amyloid, Prions, and Other Protein Aggregates , 2006 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=JOOCnik5QNAC&oi=fnd&pg=PA273&dq=(%22SNWKWWPGIFD%22+OR+%22H-SNWKWWPGIFD-OH%22)+AND+peptide&ots=uyQl_6UaVU&sig=PGgYTPFhVZDdFJW-mTNmJjJF2SE Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases RS Armen, BM Bernard, R Day - Proceedings of the , 2005 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0502068102 Brain-targeting delivery of two peptidylic inhibitors for their combination therapy in transgenic polyglutamine disease mice via intranasal administration M Yang , Q Zhang , Q Wang, KK Sorensen - Molecular , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.8b00938 Peptide-based inhibitors of amyloid assembly KL Sciarretta, DJ Gordon , SC Meredith - Methods in enzymology, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0076687906130153 Making protein interactions druggable: targeting PDZ domains KK Dev - Nature reviews Drug discovery, 2004 - nature.comhttps://www.nature.com/articles/nrd1578 Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice HA Popiel, Y Nagai , N Fujikake, T Toda - Neuroscience letters, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304394008008288 Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases HA Popiel, T Takeuchi, JR Burke, WJ Strittmatter - , 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1878747923012345 Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death H Ren, Y Nagai , T Tucker, WJ Strittmatter - Biochemical and , 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006291X01957833 Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins H Naiki , Y Nagai - Journal of biochemistry, 2009 - academic.oup.comhttps://academic.oup.com/jb/article-abstract/146/6/751/807596 Identifying new therapeutics for Huntington's disease G Schilling, DR Borchelt - Clinical Neuroscience Research, 2003 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1566277203000604 Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors BA Margulis, V Vigont, VF Lazarev, EV Kaznacheyeva - FEBS letters, 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0014579313003657
Chemical properties
Technical inquiry about: 3D-PP48217 H-SNWKWWPGIFD-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
